Patents by Inventor Bharat K. Trivedi
Bharat K. Trivedi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080227974Abstract: Novel azetidinones and pharmaceutical compositions are described, as are the methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis.Type: ApplicationFiled: July 20, 2006Publication date: September 18, 2008Inventors: Jeffrey A. Pfefferkorn, Bharat K. Trivedi
-
Patent number: 7250444Abstract: HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided.Type: GrantFiled: June 7, 2004Date of Patent: July 31, 2007Assignee: Pfizer Inc.Inventors: Robert Michael Kennedy, William Keun-Chan Park, Bruce David Roth, Yuntao Song, Bharat K. Trivedi
-
Patent number: 7244763Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.Type: GrantFiled: February 6, 2004Date of Patent: July 17, 2007Assignee: Warner Lambert Company LLCInventors: Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 7109222Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.Type: GrantFiled: December 24, 2004Date of Patent: September 19, 2006Assignee: Warner-Lambert Company, LLCInventors: Xue-Min Cheng, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi
-
Patent number: 7067538Abstract: The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.Type: GrantFiled: May 21, 2003Date of Patent: June 27, 2006Assignee: Warner-Lambert Company, LLCInventors: Larry D. Bratton, Alexander J. Bridges, David T. Connor, Steven R. Miller, Yuntao Song, Kuai-Lin Sun, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 6964983Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.Type: GrantFiled: November 2, 2004Date of Patent: November 15, 2005Assignee: Warner-Lambert Company, LLCInventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
-
Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
Patent number: 6951848Abstract: Disclosed are novel compounds having the formula or a physiologically acceptable salt, amide, ester or prodrug thereof. The compounds can be used to modulate (antagonize, agonize) chemokine receptor function. Also disclosed is a method for treating a patient having an inflammatory disease and/or viral infection comprising administering an effective amount of a compound of Formula I. In particular embodiments, the invention is a method for treating a patient infected with HIV.Type: GrantFiled: March 12, 2002Date of Patent: October 4, 2005Assignee: Millennium Pharmaceuticals, Inc.,Inventors: Geraldine C. B. Harriman, Kenneth G. Carson, Daniel L. Flynn, Michael E. Solomon, Yuntao Song, Bharat K. Trivedi, Bruce D. Roth, Christine N. Kolz, Ly Pham, Kuai-lin Sun -
Patent number: 6939875Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.Type: GrantFiled: November 2, 2004Date of Patent: September 6, 2005Assignee: Warner-Lambert CompanyInventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 6875780Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.Type: GrantFiled: January 22, 2003Date of Patent: April 5, 2005Assignee: Warner-Lambert CompanyInventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
-
Patent number: 6867224Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.Type: GrantFiled: December 19, 2002Date of Patent: March 15, 2005Assignee: Warner-Lambert CompanyInventors: Xue-Min Cheng, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi
-
Publication number: 20040209936Abstract: This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.Type: ApplicationFiled: February 6, 2004Publication date: October 21, 2004Inventors: Larry D. Bratton, Xue-Min Cheng, Noe Erasga, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi, Paul C. Unangst
-
Publication number: 20030225158Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.Type: ApplicationFiled: January 22, 2003Publication date: December 4, 2003Inventors: Bruce J. Auerbach, Larry D. Bratton, Gary F. Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst
-
Publication number: 20030207915Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia and hypercholesteremia in a mammal. The present invention also discloses method for making the disclosed compounds.Type: ApplicationFiled: December 19, 2002Publication date: November 6, 2003Inventors: Xue-Min Cheng, Gary F. Filzen, Andrew G. Geyer, Chitase Lee, Bharat K. Trivedi
-
Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
Publication number: 20030064991Abstract: Disclosed are novel compounds having the formula 1Type: ApplicationFiled: March 12, 2002Publication date: April 3, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Geraldine C.B. Harriman, Kenneth G. Carson, Daniel L. Flynn, Michael E. Solomon, Yuntao Song, Bharat K. Trivedi, Bruce D. Roth, Christine N. Kolz, Ly Pham, Kuai-lin Sun -
Patent number: 6001866Abstract: This invention provides a method for treating or preventing inflammation or atherosclerosis in mammals comprising administering an effective amount of a 15-LO inhibitor of Formula I: ##STR1## wherein: R.sup.1 is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sup.2, R.sup.3, R.sup.4, and R.sup.5 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, nitro, halo, CN, OR.sup.6, NR.sup.6 R.sup.7, --CO.sub.2 R.sup.6, CONR.sup.6 R.sup.7, CH.sub.2 OR.sup.6, or CH.sub.2 NR.sup.6 R.sup.7, and R.sup.2 and R.sup.3, and R.sup.4 and R.sup.5, when attached to adjacent ring atoms, can be --(CH.sub.2).sub.3 or 4 --;in which R.sup.6 and R.sup.7 independently are hydrogen, C.sub.1 -C.sub.6 alkyl, phenyl or benzyl, and when taken together with the nitrogen to which they are attached, R.sup.6 and R.sup.7 can complete a cyclic ring having from 3 to 7 carbon atoms; ##STR2## in which R.sup.8, R.sup.8', R.sup.9, and R.sup.9' independently are hydrogen or C.sub.1 -C.sub.6 alkyl, n is 0, 1, or 2, and Z.sup..crclbar.Type: GrantFiled: March 20, 1998Date of Patent: December 14, 1999Assignee: Warner-Lambert CompanyInventors: Joseph A. Cornicelli, Bradley D. Tait, Bharat K. Trivedi
-
Patent number: 5620997Abstract: Isothiazolones having the general structure ##STR1## where A is a monocyclic or bicyclic ring which may contain up to 3 heteroatoms selected from O, S, and N; R.sup.1 and R.sup.2 are substituent groups such as alkyl, alkoxy, hydroxy, nitro, cyano, amino, and carboxy; and R.sup.5 is alkyl, cycloalkyl, phenyl, and Het. The isothiazolones are useful as anti-retroviral agents, anti-inflammatory agents, and anti-atherosclerotic agents.Type: GrantFiled: May 31, 1995Date of Patent: April 15, 1997Assignee: Warner-Lambert CompanyInventors: Gary L. Bolton, John M. Domagala, Edward F. Elslager, Rocco D. Gogliotti, Terri S. Purchase, Joseph P. Sanchez, Bharat K. Trivedi
-
Patent number: 5593967Abstract: Novel cholecystokinin antagonists useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. They are agents useful for preventing the response to the withdrawal from chronic treatment with use of nicotine, diazepam, alcohol, cocaine, coffee, or opioids. The compounds of the invention are also useful in treating and/or preventing panic. Also disclosed are pharmaceutical compositions and methods of treatment using the antagonists as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds in diagnostic compositions.Type: GrantFiled: April 1, 1993Date of Patent: January 14, 1997Assignee: Warner-Lambert CompanyInventors: David C. Horwell, Edward Roberts, Ann Holmes, Janak K. Padia, William H. Roark, Bruce D. Roth, Bharat K. Trivedi, Jurgen Kleinschroth, David C. Rees, Reginald S. Richardson
-
Patent number: 5331006Abstract: Novel unnatural dipeptoids useful as agents in the treatment of obesity, hypersecretion of gastric acid in the gut, gastrin-dependent tumors, or as antipsychotics are disclosed. Further, the compounds are antianxiety agents and antiulcer agents. The compounds are agents useful for preventing the response to withdrawal from chronic treatment or use of nicotine, diazepam, alcohol, cocaine, caffeine, and opioids. The compounds are also useful in treating and/or preventing panic attacks. Also disclosed are pharmaceutical compositions and methods of treatment using the dipeptoids as well as processes for preparing them and novel intermediates useful in their preparation. An additional feature of the invention is the use of the subject compounds to prepare diagnostic compositions.Type: GrantFiled: July 12, 1991Date of Patent: July 19, 1994Assignee: Warner-Lambert CompanyInventors: David C. Horwell, Julian Aranda, Corinne Augelli-Szafran, Hans-Jurgen Betche, Ann Holmes, Michael D. Mullican, Martyn C. Pritchard, Reginald S. Richardson, Edward Roberts, Bruce D. Roth, Bradley D. Tait, Bharat K. Trivedi, Uwe Trostmann, Paul C. Unangst
-
Patent number: 5208224Abstract: Novel phosphorus containing compounds are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful in preventing the intestinal absorption of cholesterol and thus are useful in the treatment of hypercholesterolemia and atherosclerosis.Type: GrantFiled: March 13, 1991Date of Patent: May 4, 1993Assignee: Warner-Lambert CompanyInventors: Gary L. Bolton, Janak K. Padia, Bharat K. Trivedi
-
Patent number: RE39916Abstract: This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.Type: GrantFiled: November 28, 2005Date of Patent: November 6, 2007Assignee: Warner Lambert CompanyInventors: Bruce J. Auerbach, Larry D. Bratton, Gary Filzen, Andrew G. Geyer, Bharat K. Trivedi, Paul C. Unangst